APA (7th ed.) Citation

Hollstein, T., & März, W. (2019). Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascular pharmacology, 116, . https://doi.org/10.1016/j.vph.2019.03.002

Chicago Style (17th ed.) Citation

Hollstein, Tim, and Winfried März. "Treatment with PCSK9 Inhibitors Reduces Atherogenic VLDL Remnants in a Real-world Study." Vascular Pharmacology 116 (2019). https://doi.org/10.1016/j.vph.2019.03.002.

MLA (9th ed.) Citation

Hollstein, Tim, and Winfried März. "Treatment with PCSK9 Inhibitors Reduces Atherogenic VLDL Remnants in a Real-world Study." Vascular Pharmacology, vol. 116, 2019, https://doi.org/10.1016/j.vph.2019.03.002.